Document is current

Article History

Accepted: 6 August 2021

First Online: 18 February 2022

Declarations

:

: Julie Tran declares that she has no conflict of interest. Charles Gaulin has owns stock in Agios Pharmaceuticals and Portola Pharmaceuticals, and has received compensation for Life Science Strategy Consulting from DeciBio Consulting. Martin S. Tallman has received research funding from AbbVie, Orsenix, BioSight, GlycoMimetics, Rafael Pharmaceuticals, and Amgen; has received royalties from UpToDate; has received non-financial support from Medscape Live Symposium (EHA Congress), CRTI Workshop, Hammersmith Hospital, Hospital Britanico, Penn State University, Mumbai Hematology Group, German AML Cooperative Group, Emirates Hematology Society, Indy Hematology Review, Vanderbilt University, ASCO Direct Highlights, New Orleans Summer Cancer Meeting, Mayo Clinic, UC Davis, National Comprehensive Cancer Network (NCCN), MCI Summit of the Americas, Rambam Medical Center, and University of Miami; has participated on advisory boards for AbbVie, Daiichi Sankyo, Orsenix, Rigel, Delta-Fly Pharma, Tetraphase Pharmaceuticals, Oncolyze, Jazz Pharmaceuticals, Roche, BioSight, Novartis, Innate Pharma, Kura Oncology, and Syros Pharmaceuticals; and has received compensation for service as a consultant from Medscape Live Symposium (EHA Congress), CRTI Workshop, Prime Oncology, Penn State University, Indy Hematology Review, Targeted Oncology, Vanderbilt University, ASCO Direct Highlights, New Orleans Summer Cancer Meeting, Mayo Clinic, UC Davis, Fire Department of New York (FDNY), NCCN, MCI Summit of the Americas, and University of Miami